Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
Abgrall S, Ingle SM, May MT, Costagliola D, Mercie P, Cavassini M, Reekie J, Samji H, Gill MJ, Crane HM, Tate J, Sterling TR, Antinori A, Reiss P, Saag MS, Mugavero MJ, Phillips A, Manzardo C, Wasmuth JC, Stephan C, Guest JL, Gomez Sirvent JL, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC). Abgrall S, et al. Among authors: manzardo c. AIDS. 2013 Mar 13;27(5):803-13. doi: 10.1097/QAD.0b013e32835cb997. AIDS. 2013. PMID: 23719350
Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.
Mussini C, Manzardo C, Johnson M, Monforte Ad, Uberti-Foppa C, Antinori A, Gill MJ, Sighinolfi L, Borghi V, Lazzarin A, Miró JM, Sabin C; Late Presenter Investigators. Mussini C, et al. Among authors: manzardo c. AIDS. 2008 Nov 30;22(18):2461-9. doi: 10.1097/QAD.0b013e328314b5f1. AIDS. 2008. PMID: 19005269
Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients.
Ingle SM, May MT, Gill MJ, Mugavero MJ, Lewden C, Abgrall S, Fätkenheuer G, Reiss P, Saag MS, Manzardo C, Grabar S, Bruyand M, Moore D, Mocroft A, Sterling TR, D'Arminio Monforte A, Hernando V, Teira R, Guest J, Cavassini M, Crane HM, Sterne JA; Antiretroviral Therapy Cohort Collaboration. Ingle SM, et al. Among authors: manzardo c. Clin Infect Dis. 2014 Jul 15;59(2):287-97. doi: 10.1093/cid/ciu261. Epub 2014 Apr 24. Clin Infect Dis. 2014. PMID: 24771333 Free PMC article.
Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis.
Miro JM, Manzardo C, Mussini C, Johnson M, d'Arminio Monforte A, Antinori A, Gill MJ, Sighinolfi L, Uberti-Foppa C, Borghi V, Sabin C; Late Presenters Investigators. Miro JM, et al. Among authors: manzardo c. PLoS One. 2011;6(10):e26009. doi: 10.1371/journal.pone.0026009. Epub 2011 Oct 17. PLoS One. 2011. PMID: 22043301 Free PMC article.
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Puertas MC, Massanella M, Llibre JM, Ballestero M, Buzon MJ, Ouchi D, Esteve A, Boix J, Manzardo C, Miró JM, Gatell JM, Clotet B, Blanco J, Martinez-Picado J; MaraviBoost Collaborative Group. Puertas MC, et al. Among authors: manzardo c. AIDS. 2014 Jan 28;28(3):325-34. doi: 10.1097/QAD.0000000000000066. AIDS. 2014. PMID: 24185044 Clinical Trial.
Immunological and virological efficacy of different antiretroviral regimens initiated during acute/recent HIV infection.
Ambrosioni J, Farrera J, de Lazzari E, Nicolás D, Manzardo C, Hernández-Meneses MM, Mosquera MM, Ligero C, Marcos MA, Sánchez-Palomino S, Fernández E, Plana M, Miró JM; Hospital Clinic Acute/Recent HIV Study Group. Ambrosioni J, et al. Among authors: manzardo c. AIDS. 2020 Dec 1;34(15):2269-2274. doi: 10.1097/QAD.0000000000002685. AIDS. 2020. PMID: 32910066
Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.
Miró JM, Manzardo C, Pich J, Domingo P, Ferrer E, Arribas JR, Ribera E, Arrizabalaga J, Loncá M, Cruceta A, de Lazzari E, Fuster M, Podzamczer D, Plana M, Gatell JM; Advanz Study Group. Miró JM, et al. Among authors: manzardo c. AIDS Res Hum Retroviruses. 2010 Jul;26(7):747-57. doi: 10.1089/aid.2009.0105. AIDS Res Hum Retroviruses. 2010. PMID: 20624069 Clinical Trial.
127 results